CAS: 59557-91-4; 4-Bromo-2-Methoxyaniline

上下游产品

N,N'-bis-(4-bromo-2-methoxy-phenyl)-ureaN,N'-bis-(4-bromo-2-methoxy-phenyl)-urea N-(4-amino-2-methoxyphenyl)acetamide 2-methoxy-phenylamine 1,3-bis(2-methoxyphenyl)urea 4-bromo-1-iodo-2-methoxybenzene N-(4-bromo-2-methoxyphenyl)acetamide 6-bromo-8-methoxy-quinoline (E)-N-(4-Bromo-2-methoxy-phenyl)-3-ethoxy-acrylamide

邻甲氧基苯胺置于溴,溶剂黄146体系中,化学反应生成 4-溴-2-甲氧基苯胺
参考文献:研发用于阿尔茨海默氏病的"隐藏式"多功能药物
标题:研发用于阿尔茨海默氏病的"隐藏式"多功能药物
摘要:阿尔茨海默氏病(ad)是一种慢性,致命性和复杂性神经退行性疾病,其特征是胆碱能系统失调,金属动态平衡,淀粉样β(aβ)聚集等.因此,在大多数情况下,单靶或单功能药物是不足以达到对抗ad的理想效果.合理设计同时击中多个目标以改善药理学特征的多目标定向配体(mtdl)已被开发为针对ad的药物发现的有前途的方法.为了鉴定用于ad的多功能药物,我们开发了一种创新的方法来成功地将金属螯合剂掩盖为乙酰胆碱酯酶(ache)抑制剂.简而言之,"隐藏"剂首先穿过血脑屏障(bbb)以抑制ache的功能,然后,金属螯合剂将通过ache的酶促水解而释放.因此,在这种情况下,Ache抑制剂不仅是抗ad的单一靶标试剂,而且还是金属螯合剂的载体.在这项研究中,总共合成了14种喹啉衍生物并进行了生物学评估.两个都体外和体内结果表明,化合物9B可以有效地穿过血脑屏障,然后将9B的代谢产物8A释放到大脑中.在体外,9B具有强
DOI:10.1016/j.Ejmech.2019.05.051

专利信息

专利号:US-6235871-B1
优先权日:1997-12-03
标题:Synthesis of oligoarylamines, and uses and reagents related thereto
发明人：SINGER ROBERT A; SADIGHI JOSEPH P; BUCHWALD STEPHEN L; MACKEWITZ THOMAS
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The transition metal-catalyzed amination of aryl halides, in conjunction with an orthogonal protective group scheme, forms the basis of two routes to oligoaniline precursors. The oligoaniline precursors are soluble in a variety of common organic solvents, and are easily converted to the deprotected oligoanilines. The method allows the preparation of oligoanilines of even or odd chain lengths, and the incorporation of a variety of functional groups into the oligomers. Polyanilines of low polydispersity can also be prepared by this method.

专利号:US-2007287734-A1
优先权日:2006-06-09
标 题 :Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
发明人：GANT THOMAS G; SARSHAR SEPEHR
权利人:AUSPEX PHARMACEUTICALS INC
摘要:The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain weight loss, insulin resistance, a cardiovascular disorder, memory loss, drug dependence, a depressive disorder, a panic disorder, an obsessive-compulsive disorder, anxiety, post-traumatic stress syndrome, and any other condition in which it is beneficial to inhibit, inversely agonize or modulate a cannabinoid receptor are described.

专利号:US-2012077802-A1
优先权日:2009-06-10
标题 :Histamine h3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.

专利号:US-2012172350-A1
优先权日:2009-09-11
标题 :Histamine h3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.

专利号:US-2008039473-A1
优先权日:2006-08-08
标题:Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
发明人：GANT THOMAS G; SARSHAR SEPEHR
权利人:AUSPEX PHARMACEUTICALS INC
摘要:The present disclosure is directed to modulators of alpha-adrenergic receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of hypertension, cardiac failure, prostatitis, and benign prostatic hyperplasia, and any other condition in which it is beneficial to modulate an alpha-adrenergic receptor.

专利号:WO-2024041503-A1
优先权日:2022-08-22
标 题:Compounds targeting y220c mutant of p53
发明人：LI SUJING; LI AMIN; ZHENG QIAN; Dang Chaojie; FAN XINRUI; LONG WEI; WANG YANPING
权利人:JACOBIO PHARMACEUTICALS CO LTD
摘要:The present invention discloses compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are processes for the synthesis and use of the compounds of formula (I).